Department of Cardiology, Instituto Nacional del Tórax, Santiago, Chile.
Department of Cardiology, Hospital Militar de Santiago, Santiago, Chile.
Rev Med Chil. 2020 Sep;148(9):1295-1301. doi: 10.4067/S0034-98872020000901295.
Cardiogenic shock (CS) is uncommon in the cardiac catheterization laboratory (CCL) among patients undergoing coronary angiography. Periprocedural CS is more frequent in high-risk patients and in technically demanding procedures.
To describe the clinical outcomes of patients who underwent peripheral venoarterial extracorporeal membrane oxygenation (pVA-ECMO) for CS associated with interventional cardiology procedures.
Review of clinical records of seven patients treated between January 2014 and October 2018.
pVA-ECMO was implanted within 6 hours of the interventional cardiology procedure. All patients had coronary artery disease and one of them also had symptomatic severe aortic stenosis. One patient entered the CCL in cardiac arrest. Percutaneous coronary intervention (PCI) was performed in all patients; four patients underwent an emergency procedure and five patients experienced PCI complications. One patient undergoing transcatheter aortic valve replacement suffered acute severe aortic regurgitation. An intra-aortic balloon pump was inserted at the CCL in five patients. Six patients experienced cardiac arrest. Mean SAVE score was -4.3 and baseline lactate 55 mg/dl. pVA-ECMO mean duration was 5 ± 4 days. Survival after both hospital discharge and 12 months of follow-up was 85.7% Regarding vascular access complications, we observed one access site hematoma and one episode of cannulation site bleeding requiring surgical repair.
pVA-ECMO should be considered in patients with periprocedural CS as a bridge to recovery. Its use was associated with improved clinical outcomes in this series.
在接受冠状动脉造影的患者中,心源性休克(CS)在心脏导管室(CCL)中并不常见。围手术期 CS 在高危患者和技术要求高的手术中更为常见。
描述接受外周静脉动脉体外膜肺氧合(pVA-ECMO)治疗与介入心脏病学手术相关 CS 的患者的临床结局。
回顾 2014 年 1 月至 2018 年 10 月期间接受治疗的 7 名患者的临床记录。
pVA-ECMO 在介入心脏病学手术后 6 小时内植入。所有患者均患有冠状动脉疾病,其中 1 例还患有症状性严重主动脉瓣狭窄。1 例患者在 CCL 中出现心脏骤停。所有患者均进行经皮冠状动脉介入治疗(PCI);4 例患者进行紧急手术,5 例患者发生 PCI 并发症。1 例接受经导管主动脉瓣置换术的患者发生急性严重主动脉瓣反流。5 例患者在 CCL 中插入主动脉内球囊泵。6 例患者发生心脏骤停。平均 SAVE 评分为-4.3,基线乳酸 55mg/dl。pVA-ECMO 平均持续时间为 5±4 天。出院后和 12 个月随访后的存活率分别为 85.7%。关于血管通路并发症,我们观察到 1 例血管通路部位血肿和 1 例插管部位出血需要手术修复。
对于围手术期 CS 患者,应考虑使用 pVA-ECMO 作为恢复的桥梁。在本系列中,它的使用与改善的临床结局相关。